Biocon Ltd Analyst Rating
based on 18 analysts
55.56%
Buy
5.56%
Hold
38.89%
Sell
Based on 18 analysts offering long term price targets for Biocon Ltd. An average target of ₹342.83
Source: S&P Global Market Intelligence
Biocon Ltd Share analysis
Biocon Ltd price forecast by 18 analysts
Downside of
High
₹460
Target
₹342.83
Low
₹235
Biocon Ltd target price ₹342.83, a slight downside of -6.8% compared to current price of ₹356.7. According to 18 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon Ltd revenue growth forecast
Expected growth rate Q1, FY2026:24.25%
Forecast
Actual
Including amortisation and stock based compensations
Biocon Ltd EPS growth forecast
EPS estimate Q1, FY2026:22.42%
Forecast
Actual
Source: S&P Global Market Intelligence
Biocon Ltd Performance
Day's Low
Day's High
₹355.5₹369.3552 Week's Low
52 Week's High
₹237.65₹395.8
| Returns % | |
| 1 Month Return | + 5.86 % |
| 3 Month Return | -2.32 % |
| 1 Year Return | + 54.14 % |
| Market Stats | |
| Previous Close | ₹367.85 |
| Open | ₹368.40 |
| Volume | 17.67L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹44,164.07Cr |
Biocon Ltd Key Statistics
| P/E Ratio | 30.58 |
| PEG Ratio | 3.89 |
| Market Cap | ₹44,164.07 Cr |
| P/B Ratio | 2.91 |
| EPS | 10.81 |
| Dividend Yield | 0.19 |
| Sector | Pharmaceuticals |
| ROE | 0.97 |
Biocon Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹44,164.07 Cr | 5.12% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹1,57,368.45 Cr | 44.82% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,14,215.13 Cr | 52.67% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹29,248.37 Cr | -0.49% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,17,434.94 Cr | 43.08% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Biocon Ltd Mutual Fund Holdings
About Biocon Ltd
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Share Price: ₹356.70 per share as on 12 Dec, 2024 04:01 PM
Market Capitalisation: ₹44,164.07Cr as of today
Revenue: ₹3,545.00Cr as on September 2024 (Q3 24)
Net Profit: ₹27.10Cr as on September 2024 (Q3 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon Ltd |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Biocon Ltd
Biocon Sells Stake in Syngene, Receives IP Recognition - 11 Dec, 2024
Biocon sold 80 lakh shares of Syngene International for Rs 686 crore, lowering its stake to 52.46%. Additionally, Biocon Biologics was recognized as an Asia IP Elite for 2024, continuing its legacy of excellence in intellectual property.Biocon Divests Stake in Syngene International - 10 Dec, 2024
Biocon Ltd announced plans to divest a 2% stake in Syngene International, successfully selling 80 lakh shares for Rs 686 crore, reducing its ownership to 52.46%. This strategic move reflects Biocon's ongoing adjustments in its investment portfolio.Biocon Faces Loss Amid USFDA Inspection Report - 09 Dec, 2024
Biocon announced a consolidated net loss of Rs 16 crore in Q2 FY25, alongside receiving a Voluntary Action Indicated status from the USFDA for its Bengaluru API facility.Biocon Electric Launches New Switches Nationwide - 05 Dec, 2024
Biocon Electric has launched a new range of high-quality switches to meet growing demand in India. The company aims to expand its presence from 14 to 20 states by next year, focusing on providing affordable, innovative electrical solutions for residential and commercial spaces.Biocon Secures FDA Approval for Yesintek Biosimilar - 02 Dec, 2024
Biocon Biologics' Yesintek, a biosimilar to Johnson & Johnson's Stelara, received USFDA approval, boosting Biocon's market position and stock performance. The approval is expected to drive growth in international markets.Biocon Biologics Secures FDA Approval for YESINTEK - 01 Dec, 2024
Biocon Biologics has received US FDA approval for YESINTEK, a biosimilar for treating Crohn's disease and other autoimmune conditions, with commercialization planned by February 2025.Biocon Advances Diabetes Care Project, Analyst Recommends Buy - 28 Nov, 2024
Biocon Biologics reported progress in its diabetes care initiative in Ethiopia. An analyst recommends buying Biocon stock with a target price of ₹320-325.Biocon Ltd Shows Bullish Momentum Amid Market Interest - 26 Nov, 2024
Biocon Ltd traded between Rs 336.05 and Rs 355.45, nearing its 52-week high. Analysts recommend a buy above Rs 355.45, targeting Rs 360.00, while maintaining a positive outlook on growth potential.Geojit Financial Services Recommends Accumulate on Biocon - 21 Nov, 2024
Geojit Financial Services has reiterated an 'Accumulate' rating on Biocon Ltd with a target price of Rs. 376. The company's revenue grew 3.7% YoY, driven by strong biosimilar sales, despite a decline in the generics segment. Biocon's growth prospects are bolstered by a VAI classification for its Biologics Park and early signs of recovery in its research services arm, Syngene.Biocon Biologics Plans to Reduce Debt by $300 Million - 19 Nov, 2024
Biocon Biologics aims to reduce $300 million in acquisition debt within a year, following a recent refinancing of $1.1 billion. The company anticipates growth in its biosimilar and insulin markets, with plans to double insulin capacity in Malaysia. A positive USFDA inspection outcome could facilitate the launch of a new biosimilar in the US.Biocon Group Focuses on Debt Reduction and Growth - 12 Nov, 2024
Biocon Group aims to reduce debt while navigating challenges in its generics business. Despite an 8% YoY revenue increase, generics revenue declined 8%. The company is optimistic about growth in the second half of the year, driven by investments in biosimilars and upcoming product launches.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 5.90% to 5.93% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Shree Ganesh Remedies Ltd has given 126.8% return, outperforming this stock by 129.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Vimta Labs Ltd has given 117.0% return, outperforming this stock by 62.8%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 18.89% to 18.75% in Sep 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 4.59K Cr → 3.64K Cr (in ₹), with an average decrease of 20.7% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 659.7 Cr → -16.0 Cr (in ₹), with an average decrease of 102.4% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, BIOCON stock has moved down by -2.0%
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 8.69% to 7.97% in Sep 2024 quarter
Biocon Ltd Financials
Index Inclusions
Biocon Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.93% | 0.47 | |
| Mutual Funds | 7.97% | ||
| Retail Investors | 18.75% | ||
| Others | 6.72% | 14.14 |
Biocon Ltd Key Indicators
Biocon Ltd Valuation
Biocon Ltd in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (30.58x)
December 11, 2024
Industry (56.82x)
December 11, 2024
Highest (118.86x)
September 27, 2018
Biocon Ltd Earnings and Dividends
Biocon Ltd Earnings Results
Biocon Ltd’s net profit fell -112.74% since last year same period to ₹-16Cr in the Q2 2024-2025. On a quarterly growth basis, Biocon Ltd has generated -102.43% fall in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.54%.
Read More about Dividends
Biocon Ltd Technicals Summary
Bearish
Neutral
Bullish
Biocon Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Biocon Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Biocon Ltd shares.
Biocon Ltd (BIOCON) share price today is ₹356.7
Biocon Ltd is listed on NSE
Biocon Ltd is listed on BSE
- Today’s highest price of Biocon Ltd is ₹369.35.
- Today’s lowest price of Biocon Ltd is ₹355.5.
PE Ratio of Biocon Ltd is 30.58
PE ratio = Biocon Ltd Market price per share / Biocon Ltd Earnings per share
Today’s traded volume of Biocon Ltd(BIOCON) is 17.67L.
Today’s market capitalisation of Biocon Ltd(BIOCON) is ₹44164.07Cr.
| Biocon Ltd(BIOCON | Price |
|---|---|
52 Week High | ₹395.8 |
52 Week Low | ₹237.65 |
Biocon Ltd(BIOCON) share price is ₹356.7. It is down -9.88% from its 52 Week High price of ₹395.8
Biocon Ltd(BIOCON) share price is ₹356.7. It is up 50.09% from its 52 Week Low price of ₹237.65
| Biocon Ltd(BIOCON | Returns |
|---|---|
1 Day Returns | -11.15% |
1 Month Returns | 5.86% |
3 Month Returns | -2.32% |
1 Year Returns | 54.14% |